Conventional approaches to the treatment of recurrent mantle cell lymphoma (MCL) yield unsatisfactory results. We describe a patient with recurrent MCL in leukemic phase refractory to chemotherapy who was successfully treated with allogeneic bone marrow transplantation. At last follow-up 1 year post-transplant, the patient was in complete remission and had limited chronic graft-versus-host disease. Keywords: mantle cell lymphoma; allogeneic transplant Mantle cell lymphoma (MCL) is a distinct clinicopathologic entity with unique morphologic, immunophenotypic, cytogenetic and molecular genetic findings. 1 The vast majority of patients present with symptomatic advanced disease for which the prognosis is poor. Median survival is only 24-36 months using combination chemotherapy regimens such as cyclophosphamide, doxorubicin, vincristine and prednisone.
Mantle cell lymphoma (MCL) is a distinct clinicopathologic entity with unique morphologic, immunophenotypic, cytogenetic and molecular genetic findings. 1 The vast majority of patients present with symptomatic advanced disease for which the prognosis is poor. Median survival is only 24-36 months using combination chemotherapy regimens such as cyclophosphamide, doxorubicin, vincristine and prednisone. 2, 3 Interferon maintenance therapy does not prolong survival. 4 Relapse of disease is uniform, occurring on average 10-14 months after completion of initial chemotherapy.
Optimal treatment of patients with MCL in relapse is unclear, with median survival of 8-12 months reported using a variety of approaches including involved-field radiotherapy, and single or multi-agent salvage chemotherapy. Few patients with recurrent MCL have been treated with high-dose therapy and autologous stem cell rescue; however, preliminary reports demonstrated that relapse occurred in the majority. 5, 6 A plateau in diseasefree survival has not been clearly observed following autologous transplantation, although follow-up is early. 7 We describe a patient with relapsed MCL in leukemic phase resistant to aggressive salvage chemotherapy treated successfully with allogeneic bone marrow transplantation 
Case report
A 55-year-old white male with relapsed MCL underwent allogeneic BMT. The diagnosis of MCL was based on characteristic cell morphology and immunophenotyping (CD5, CD19 and CD20 positive, and CD23 negative). The patient had received three prior combination chemotherapy regimens, and most recently recurred with nodal and extranodal (peripheral blood, marrow and spleen) sites of disease. Pre-transplant chemotherapy with infusional doxorubicin, cisplatin, cytarabine and methylprednisolone (ASHAP) 8 given to cytoreduce the tumor was unsuccessful, with progressive disease manifested by the appearance of circulating tumor cells with blastic variant morphology. The transplant preparative regimen included total body irradiation (TBI) administered in 175 cGy fractions twice a day days −8 to −5 (total dose 1225 cGy), etoposide 30 mg/kg day −4, and cyclophosphamide 60 mg/kg/day days −3 and −2, followed by infusion on day 0 of bone marrow obtained from his HLA-matched brother. Graftversus-host disease (GVHD) prophylaxis consisted of cyclosporine and corticosteroids, the latter started on day +7 and tapered off by day +55.
Interestingly, the circulating leukemic cell burden did not respond to the TBI-based preparative regimen, with greater absolute numbers of blast cells remaining in the peripheral blood at 10 days post-transplant compared to the number present upon initiation of the preparative regimen (Figure 1) . At day +20, a dramatic decline in the peripheral blood absolute leukemic cell count was observed. By day +27, no circulating tumor cells were present by light microscopic examination, however, flow cytometry of the peripheral blood lymphocytes demonstrated a persistent clonal population of cells with kappa light chain restriction. On day +69, physical examination and CAT scans demonstrated no enlarged lymph nodes and bone marrow aspirate and biopsy revealed normal lymphocyte morphology and no light chain clonal excess by flow cytometry. Complete donor engraftment was documented by hypervariable minisatellite probes (VNTR) in a sample of the marrow aspirate. 9 One year after allogeneic BMT the patient remains in complete remission, with limited chronic GVHD involving the skin. At last follow-up, bone marrow aspirate and biopsy revealed no evidence of lymphoma based on microscopic examination and flow cytometric evaluation. Studies to determine bcl-1 rearrangement and overexpression were not performed.
Discussion
Treatment of recurrent MCL using conventional options yields unsatisfactory results. New therapeutic approaches for managing this entity are needed. We described a patient with recurrent MCL in leukemic phase refractory to aggressive salvage chemotherapy who achieved a durable complete remission with allogeneic BMT. However, follow-up of this patient is short and it is unclear if this approach is curative. It is notable that the transplant preparative regimen did not immediately ablate the circulating tumor cells. The absolute number of circulating tumor cells was actually greater 10 days post-transplant than that present at initiation of the preparative regimen. Disease response was initially observed approximately 20 days after completing the transplant preparative regimen, followed by subsequent documentation of complete remission 2 months post-transplant. Although the patient received corticosteroids for GVHD prophylaxis during this interval, it is unlikely that this agent alone resulted in the dramatic and sustained response observed given the lack of response to ASHAP administered pre-transplant. Gradual tumor responses and delayed time to achieve complete remission have also been observed after allogeneic BMT for other B cell malignancies, such as chronic lymphocytic leukemia and multiple myeloma. Although speculative, a graftversus-tumor effect may be the explanation for this observation. A graft-versus-tumor effect has not been observed in MCL, although occasional patients with other B cell lymphoproliferative disorders have responded to donor lymphocyte infusions given for recurrent disease post-allogeneic BMT. 10 Malignant cells present within the blood and bone marrow, and the large fraction of patients who fail to achieve significant tumor responses with salvage therapy, preclude autologous transplantation as a treatment option in most patients with relapsed MCL. Methods used to purge malignant cells from autologous stem cell products are not consistently effective in this disease. 11 Allogeneic BMT eliminates the concern of reinfusing tumor cells present in the stem cell product, and may also provide a graft-versustumor effect. Allogeneic transplantation as therapy of MCL has not been pursued, perhaps due to the advanced age of most patients and the higher treatment-related mortality of this approach. 'Low intensity' preparative regimens may reduce the toxicity and broaden the application of this approach in older patients. 12 
